EverSource Wealth Advisors LLC Has $4.27 Million Stock Holdings in CRISPR Therapeutics AG $CRSP

EverSource Wealth Advisors LLC grew its stake in CRISPR Therapeutics AG (NASDAQ:CRSP) by 56.1% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 89,683 shares of the company’s stock after acquiring an additional 32,218 shares during the period. EverSource Wealth Advisors LLC’s holdings in CRISPR Therapeutics were worth $4,266,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also bought and sold shares of the stock. Cerity Partners LLC boosted its position in CRISPR Therapeutics by 3.0% during the second quarter. Cerity Partners LLC now owns 6,541 shares of the company’s stock valued at $318,000 after purchasing an additional 190 shares during the last quarter. Peapack Gladstone Financial Corp increased its position in shares of CRISPR Therapeutics by 3.0% during the 2nd quarter. Peapack Gladstone Financial Corp now owns 6,973 shares of the company’s stock worth $339,000 after purchasing an additional 200 shares during the last quarter. Allworth Financial LP raised its stake in shares of CRISPR Therapeutics by 2.7% during the 4th quarter. Allworth Financial LP now owns 9,550 shares of the company’s stock worth $501,000 after purchasing an additional 249 shares in the last quarter. Meeder Advisory Services Inc. raised its stake in shares of CRISPR Therapeutics by 6.6% during the 4th quarter. Meeder Advisory Services Inc. now owns 4,392 shares of the company’s stock worth $230,000 after purchasing an additional 270 shares in the last quarter. Finally, Hedges Asset Management LLC raised its stake in shares of CRISPR Therapeutics by 1.2% during the 4th quarter. Hedges Asset Management LLC now owns 22,775 shares of the company’s stock worth $1,194,000 after purchasing an additional 275 shares in the last quarter. Institutional investors own 69.20% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms recently weighed in on CRSP. Weiss Ratings reissued a “sell (d-)” rating on shares of CRISPR Therapeutics in a research note on Friday, July 17th. HC Wainwright reaffirmed a “buy” rating and set a $80.00 price target on shares of CRISPR Therapeutics in a research report on Wednesday, July 8th. Evercore reiterated an “outperform” rating and issued a $76.00 price target on shares of CRISPR Therapeutics in a research note on Monday, May 11th. UBS Group set a $80.00 price objective on shares of CRISPR Therapeutics in a research report on Friday, June 12th. Finally, Sanford C. Bernstein boosted their price objective on shares of CRISPR Therapeutics from $50.00 to $56.00 and gave the stock a “market perform” rating in a research note on Wednesday, May 13th. One research analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating, seven have assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, CRISPR Therapeutics has a consensus rating of “Moderate Buy” and a consensus target price of $67.78.

Insider Buying and Selling at CRISPR Therapeutics

In other news, insider Naimish Patel sold 3,786 shares of the stock in a transaction on Friday, May 29th. The stock was sold at an average price of $55.62, for a total transaction of $210,577.32. Following the sale, the insider directly owned 19,357 shares of the company’s stock, valued at approximately $1,076,636.34. This represents a 16.36% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders own 5.20% of the company’s stock.

CRISPR Therapeutics Trading Up 0.2%

CRSP stock opened at $47.64 on Thursday. CRISPR Therapeutics AG has a one year low of $44.12 and a one year high of $78.48. The stock has a market cap of $4.59 billion, a price-to-earnings ratio of -7.66 and a beta of 1.71. The company has a fifty day moving average price of $52.60 and a two-hundred day moving average price of $52.49. The company has a debt-to-equity ratio of 0.32, a current ratio of 17.97 and a quick ratio of 17.96.

CRISPR Therapeutics (NASDAQ:CRSP) last issued its quarterly earnings results on Tuesday, March 31st. The company reported ($1.28) earnings per share (EPS) for the quarter. The company had revenue of $1.46 million during the quarter. CRISPR Therapeutics had a negative net margin of 13,856.54% and a negative return on equity of 25.66%. Equities analysts anticipate that CRISPR Therapeutics AG will post -4.9 EPS for the current year.

CRISPR Therapeutics Profile

CRISPR Therapeutics AG is a biopharmaceutical company specializing in the development of gene-editing therapies based on the CRISPR/Cas9 platform. The company applies its proprietary technology to modify genes in human cells, aiming to create durable treatments for a range of serious diseases. Its research and development efforts focus on both ex vivo and in vivo applications, enabling targeted correction or disruption of disease-causing genes.

Among its lead programs is CTX001, an ex vivo edited cell therapy designed to treat sickle cell disease and transfusion-dependent β-thalassemia in collaboration with Vertex Pharmaceuticals.